ResearcherCenter of Medical Innovation and Translational Research, The University of OsakaNo recent work listed
Ayumu Asai
Matched on OpenAlex author ID A5112642735. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 6
- Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
- Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer. Co-author DOI 10.18632/oncotarget.28035↗
- Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. Co-author DOI 10.3390/cells9071645↗
- A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cmdc.201900324↗
- The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Co-author DOI 10.3892/ijo.2017.4219↗
- Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Co-author DOI 10.3892/ol.2018.8357↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hideshi Ishii · 5 shared papers, 2018–2022 · strength 0.51
- Paper Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer. DOI 10.18632/oncotarget.28035↗
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. DOI 10.3390/cells9071645↗
- Yuichiro Doki · 5 shared papers, 2018–2022 · strength 0.44
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. DOI 10.3390/cells9071645↗
- Paper The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. DOI 10.3892/ijo.2017.4219↗
- Hidetoshi Eguchi · 4 shared papers, 2018–2022 · strength 0.36
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. DOI 10.3390/cells9071645↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Hirofumi Akita · 3 shared papers, 2019–2022 · strength 0.30
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. DOI 10.3390/cells9071645↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Tadafumi Asaoka · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Yoshifumi Iwagami · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Kunihito Gotoh · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Katsunori Matsushita · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Daisaku Yamada · 3 shared papers, 2018–2020 · strength 0.22
- Paper Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. DOI 10.3390/cells9071645↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Ryota Chijimatsu · 1 shared paper, 2021 · strength 0.14
- Yu Takeda · 1 shared paper, 2020 · strength 0.09
- Kosuke Taketo · 1 shared paper, 2018 · strength 0.08
- Kazuhiko Ogawa · 1 shared paper, 2018 · strength 0.08
- Satoshi Obika · 1 shared paper, 2019 · strength 0.07
- Hideshi Ishii · 1 shared paper, 2019 · strength 0.07
- Reishi Toshiyama · 1 shared paper, 2018 · strength 0.06
- Tomofumi Ohashi · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.